Cargando…
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with (211)At Intraperitoneal Radioimmunotherapy
Intraperitoneal (211)At-based targeted α-therapy (TAT) may hold great promise as an adjuvant therapy after surgery and chemotherapy in epithelial ovarian cancer to eradicate any remaining undetectable disease. This implies that it will also be delivered to patients possibly already cured by the prim...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Society of Nuclear Medicine
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841246/ https://www.ncbi.nlm.nih.gov/pubmed/35798559 http://dx.doi.org/10.2967/jnumed.121.263349 |